Strata acted as exclusive financial adviser to LGC
KBioscience
Life Sciences
2011


Advised LGC on the acquisition of KBioscience to create a market leader in genomic services and solutions
Transaction Overview
Strata acted as exclusive financial adviser to Bridgepoint-backed, international lab testing group LGC on the combination of LGC’s Genomics division with leading single-plex genotyping solutions provider KBioscience by way of acquisition to create a market leader in genomic services and solutions
The transaction enabled LGC to transform the smallest of its four divisions into a differentiated international genomics products and services business with strong growth prospects and attractive margins
The founders of KBioscience remain partners and significant shareholders in the enlarged business alongside LGC
LGC was acquired by funds managed by Bridgepoint for some £257 million in February 2010
Transaction Rationale
Highly complementary services, products and customers in adjacent areas of the genomics market
- LGC expertise in high throughput / automated sequence analysis for discovery
- KBioscience expertise in bespoke / low to medium throughput genotyping
- Similar highly scientific cultures and premium quality reputations
- Enables the provision of broader but complementary suite of services and solutions to an enlarged customer base
Limited geographic overlap
- KBioscience strong in UK and North America
- LGC strong in Continental Europe and Asia
LGC benefits from entrepreneurial culture and cost / client service focus of KBioscience
- KBioscience benefits from LGC’s global network and administrative resources
- Access to capital to drive sector consolidation
- Critical mass to resource future R&D strategy
Interested in working with us?
Our partners are available to discuss potential mandates across all sectors and transaction types.
Contact Us


